VF
ALGS icon

Virtu Financial’s Aligos Therapeutics ALGS Stock Holding History

Virtu Financial’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-492
Closed -$4K – 1325
2024
Q2 		$4K Buy
+492
New +$8.65K ﹤0.01% 1189
2023
Q3 		– Sell
-734
Closed -$18K – 1249
2023
Q2 		$18K Buy
+734
New +$19.7K ﹤0.01% 1277

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial's ALGS Position: Q3 2024 in Review

Virtu Financial sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 492 shares — an estimated $4K sold.

Virtu Financial first reported a position in ALGS in Q2 2023 and held it in 2 quarters. The position peaked at $18K in Q2 2023. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • Virtu Financial reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Virtu Financial sold 492 Aligos Therapeutics shares in Q3 2024, an estimated $4K.
  • Virtu Financial first reported a position in Aligos Therapeutics in Q2 2023 and held it in 2 quarters.
  • Virtu Financial's Aligos Therapeutics position peaked at $18K in Q2 2023.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.